Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/?Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)
Complete Title: A Phase 3, Multicenter, Open-label, Randomized Study to Compare the
Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+
Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma,
Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
Trial Phase: III
Investigator: David Zhen
This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician`s choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).
Keywords:
- Gastroesophageal Junction Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.